- Home
- BHM vs ALGS Comparison
BHM vs ALGS Comparison
Compare BHM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHM | ALGS |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 34.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BHM | ALGS |
|---|---|---|
| Price | $8.02 | $5.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $15.00 | ★ $39.33 |
| AVG Volume (30 Days) | 2.7K | ★ 46.9K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,734,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.05 | $3.98 |
| 52 Week High | $13.30 | $13.69 |
Technical Indicators
Market Signals| Indicator | BHM | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 38.54 |
| Support Level | $8.11 | $4.80 |
| Resistance Level | $8.97 | $6.91 |
| Average True Range (ATR) | 0.29 | 0.44 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 34.38 | 14.68 |
Price Performance
Historical ComparisonAbout BHM Bluerock Homes Trust Inc.
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.